比伐卢定在直接经皮冠状动脉介入术治疗应用的临床研究进展

Clinical Development of Divalirudin in Primary Percutaneous Coronary Intervention

比伐卢定是水蛭素类衍生物,通过直接凝血酶而发挥抗凝作用。相关基础及临床研究证实其可以作为普通肝素和血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂的替代药物应用于非高危患者的经皮冠状动脉介入术治疗,比伐卢定是否能够同样安全、有效地应用于行直接经皮冠状动脉介入术治疗的急性ST段抬高型心肌梗死患者仍在继续研究。

Bivalirudin is an derivatives of hirudin,which can direct antithrombin inhibitor. Large clinical studies and basic researches have demonstrate that bivalirudin could replace unfractionated heparin plus a glycoprotein Ⅱb / Ⅲa inhibitor in patients without high risk undergoing percutaneous coronary intervention. Whether the benefits will continue in patients with ST-elevated myocardial infarction,who will receive primary percutaneous coronary intervention is still in investigating.